Consolidated Statements of Stockholders Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series B Preferred Stock [Member]
Balance at Dec. 31, 2017	$ (3,410)	$ 4	$ 192,670	$ (194,170)	$ (1,914)	$ 0
Balance (in shares) at Dec. 31, 2017		3,671,014				0
Stock-based compensation	676	$ 0	676	0	0	$ 0
Fair Value of Warrants issued	9	0	9	0	0	0
Series A preferred stock dividends	(59)	0	0	(59)	0	0
Net Loss	(2,316)	0	0	(2,316)	0	0
Non-controlling interest	(10)		0	0	(9)	0
Balance at Mar. 31, 2018	(5,109)	$ 4	193,355	(196,545)	(1,923)	$ 0
Balance (in shares) at Mar. 31, 2018		3,671,014				0
Balance at Dec. 31, 2018	14,159	$ 15	230,754	(219,461)	(2,909)	$ 5,760
Balance (in shares) at Dec. 31, 2018		15,482,083				9,161
Stock-based compensation	64	$ 0	64	0	0	$ 0
Series A preferred stock dividends	(61)	0	0	(61)	0	0
Issuance of SYN Biomics Stock	17	0	(36)	0	53	0
Conversion of Series B Preferred Stock to Common	0	$ 1	1,035	(398)	0	$ (638)
Conversion of Series B Preferred Stock to Common (in shares)		900,869				(1,036)
Net Loss	(3,512)	$ 0	0	(3,512)	0	$ 0
Non-controlling interest	(16)		0	0	(16)	0
Balance at Mar. 31, 2019	$ 10,651	$ 16	$ 231,817	$ (223,432)	$ (2,872)	$ 5,122
Balance (in shares) at Mar. 31, 2019		16,382,952				8,125